Rivastigmine for refractory REM behavior disorder in Mild Cognitive Impairment

Valerio Brunetti, Anna Losurdo, Elisa Testani, Leonardo Lapenta, Paolo Mariotti, Camillo Marra, Paolo Maria Rossini, Giacomo Della Marca

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. Methods: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). Results: RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. Conclusions: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.

Original languageEnglish
Pages (from-to)267-273
Number of pages7
JournalCurrent Alzheimer Research
Volume11
Issue number3
DOIs
Publication statusPublished - 2014

Keywords

  • Acetylcholine
  • Acetylcholinesterase inhibitors
  • Alzheimer disease
  • Cholinergic pathways
  • MCI
  • Mild cognitive impairment
  • RBD
  • REM
  • REM behavior disorder
  • Rivastigmine (RVT)
  • Sleep

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Rivastigmine for refractory REM behavior disorder in Mild Cognitive Impairment'. Together they form a unique fingerprint.

Cite this